Company intelligence / Profile preview

Modis Therapeutics

Oakland, California, United States

Ownership: Private
Development stage: Other

Overview

Lead candidate MT1621 demonstrated clinical benefit in patients with thymidine kinase 2 deficiency (TK2d), with encouraging results in both animal models and compassionate-use patients. The drug has orphan and rare pediatric disease designation in the US and EU; registration-enabling studies and regulatory filings were planned prior to acquisition.

Therapeutic areas: Rare Diseases
Modalities: Small moleculeNucleoside
Industry: Biotech

Beyond the preview

Go deeper on Modis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modis Therapeutics.

Explore the full profile